Nexavar (sorafenib) meets goal in thyroid cancer trial
FRANKFURT (Reuters) - German drugmaker Bayer said its cancer treatment Nexavar (sorafenib) reached a
goal of improving the survival of patients with radioactive iodine (RAI) refractory differentiated thyroid cancer
in a late-stage clinical trial.
Source: Modern Medicine - Category: Journals (General) Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | General Medicine | Thyroid | Thyroid Cancer